Core Viewpoint - Xianju Pharmaceutical's stock has shown a mixed performance in recent trading, with a slight increase in price and notable changes in trading volume and shareholder structure [1][2]. Group 1: Stock Performance - On November 11, Xianju Pharmaceutical's stock rose by 2.06%, reaching 9.92 CNY per share, with a trading volume of 213 million CNY and a turnover rate of 2.20%, resulting in a total market capitalization of 9.813 billion CNY [1]. - Year-to-date, the stock price has increased by 3.98%, with a 4.86% rise over the last five trading days, a 3.55% increase over the last 20 days, but a decline of 6.42% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Xianju Pharmaceutical reported a revenue of 2.826 billion CNY, a year-on-year decrease of 12.71%, and a net profit attributable to shareholders of 407 million CNY, down 23.29% year-on-year [2]. - Cumulatively, the company has distributed 2.031 billion CNY in dividends since its A-share listing, with 989 million CNY distributed over the last three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders for Xianju Pharmaceutical was 49,600, a decrease of 0.82% from the previous period, with an average of 19,854 circulating shares per shareholder, an increase of 0.83% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 8.126 million shares as a new shareholder, while the Southern CSI 1000 ETF is the eighth largest, holding 7.238 million shares, a decrease of 97,000 shares from the previous period [3]. Group 4: Business Overview - Xianju Pharmaceutical, established on June 26, 2000, and listed on January 12, 2010, specializes in the research, production, and sales of steroid raw materials and formulations [1]. - The company's main business revenue composition includes corticosteroids (63.39%), gynecological and family planning medications (20.69%), other products (9.21%), and anesthetics and muscle relaxants (6.71%) [1].

10月16日，仙琚制药跌0.20%，成交额1.09亿元。两融数据显示，当日仙琚制药获融资买入额1311.19万 元，融资偿还1604.82万元，融资净买入-293.63万元。截至10月16日，仙琚制药融资融券余额合计5.67 亿元。 截至9月30日，仙琚制药股东户数5.00万，较上期增加0.00%；人均流通股19691股，较上期增加0.00%。 2025年1月-6月，仙琚制药实现营业收入18.69亿元，同比减少12.56%；归母净利润3.08亿元，同比减少 9.26%。 分红方面，仙琚制药A股上市后累计派现20.31亿元。近三年，累计派现9.89亿元。 机构持仓方面，截止2025年6月30日，仙琚制药十大流通股东中，南方中证1000ETF（512100）位居第 九大流通股东，持股733.51万股，相比上期增加140.94万股。香港中央结算有限公司、兴全合丰三年持 有混合（009556）退出十大流通股东之列。 责任编辑：小浪快报 融资方面，仙琚制药当日融资买入1311.19万元。当前融资余额5.65亿元，占流通市值的5.81%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，仙琚制药10月16日融券偿 ...

Group 1: Company Overview and Market Expansion - The company's overseas market expansion has seen an increase in product export ratio from 28.54% in 2024 to 38.6% in the first half of 2025, indicating a consistent upward trend in international sales [2] - The primary overseas markets include Europe, North America, South America, and India [3] Group 2: Product Development and Production - The joint venture with Huahai Pharmaceutical focuses on high-end steroid raw materials, with a total of 13 high-end steroid raw material products planned, and two production workshops have entered trial production [3][4] - The company aims to enhance production efficiency and product quality by applying synthetic biology and other technologies [5] Group 3: Market Applications and Trends - Steroid drugs are categorized into sex hormones, progestogens, corticosteroids, and others, with applications in hormone replacement therapy, immune response treatment, and chronic disease management [4] - The restructuring of the global pharmaceutical supply chain presents new opportunities, particularly in reproductive health and chronic disease management for the aging population [5] Group 4: Competitive Strategy - The company emphasizes full supply chain collaboration as a core competitive advantage, focusing on optimizing raw material sourcing, intermediate production, and raw material drug development [5] - Plans to extend into high-value areas such as high-end intermediates and specialty raw materials are underway, supported by a complete industrial chain from steroid drug raw materials to intermediates and APIs [5]

Core Insights - Changde is transforming its industrial landscape by integrating synthetic biology into its development strategy, aiming to become a national leader in the bio-manufacturing sector [1][3] - The second "Innovation and Entrepreneurship Competition for Synthetic Biology Manufacturing" is set to attract innovative projects with industrial potential, supported by various top-tier research institutions and investment firms [1][4] Group 1: Changde's Industrial Evolution - Changde's bio-manufacturing roots trace back to the 1960s with the fermentation process for MSG, evolving into a significant global production base for enzyme preparations and steroid drugs, with a 62% global market share in glyphosate production and 70% in corticosteroids [3] - The city has established synthetic biology as a core pillar of its modern industrial system, supported by provincial policies and the first local regulations on synthetic biology manufacturing in China [3][4] Group 2: Competition Structure and Objectives - The competition features a dual-track mechanism with "Creative Group" for students and researchers focusing on original innovation, and "Growth Group" for registered SMEs emphasizing commercialization and industry collaboration [4][5] - The competition covers nine key areas including bio-food, bio-pharmaceuticals, and bio-materials, aligning with national strategies for green development and health [6] Group 3: Resource Support and Incentives - The competition aims to create a strong ecosystem for innovation, providing financial support, access to industrial resources, and a comprehensive service mechanism for project implementation [8] - Winners will share approximately 1.5 million yuan in prizes and benefit from various policy supports, including talent subsidies and access to a fund matrix of around 40 billion yuan for financial services [8] Group 4: Participation and Timeline - The registration for the second competition has officially opened, with a timeline from September to mid-November for project submissions, followed by preliminary and final rounds leading to a decision in January 2026 [9]

9月17日，仙琚制药跌1.07%，成交额1.72亿元。两融数据显示，当日仙琚制药获融资买入额1839.31万 元，融资偿还2446.90万元，融资净买入-607.59万元。截至9月17日，仙琚制药融资融券余额合计6.41亿 元。 融资方面，仙琚制药当日融资买入1839.31万元。当前融资余额6.39亿元，占流通市值的6.36%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，仙琚制药9月17日融券偿还0.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 3048.00元；融券余量15.81万股，融券余额160.63万元，超过近一年80%分位水平，处于高位。 资料显示，浙江仙琚制药股份有限公司位于浙江省仙居县福应街道现代工业集聚区丰溪西路15号，成立 日期2000年6月26日，上市日期2010年1月12日，公司主营业务涉及甾体原料药和制剂的研制、生产与销 售。主营业务收入构成为：皮质激素63.39%，妇科及计生用药20.69%，其他9.21%，麻醉及肌松用药 6.71%。 截至9月8日，仙琚制药股东户数5.00万，较上期增加8.70%；人均流通股19691股，较上期减少8.00%。 2025 ...